- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00865254
Prize Reinforcement for Smoking Cessation
27 juni 2013 uppdaterad av: David Ledgerwood, Wayne State University
Nicotine dependence is prevalent in society, cigarette smoking is associated with several known health risks, and most dependent individuals find it very difficult to stop smoking cigarettes.
The present study will test the efficacy of a behavioral smoking cessation treatment, prize-based contingency management, that has not undergone rigorous study with respect to smoking, it but has demonstrated efficacy in reducing use of other substances (e.g.
cocaine).
If efficacious, prize-based contingency management would add to our repertoire of efficacious smoking cessation treatments.
Studieöversikt
Status
Avslutad
Betingelser
Detaljerad beskrivning
Contingency management (CM) treatments are efficacious in reducing substance use.
A relatively new approach, called prize-based CM, which uses prizes to reinforce substance abstinence, is effective in decreasing certain types of substance use, but its efficacy has not been evaluated in the treatment of cigarette smoking.
One purpose of the current study is to assess the efficacy of a prize reinforcement intervention for reducing cigarette smoking.
A second purpose is to test the differential efficacy of two schedules of reinforcement, using cigarette smoking as an exemplar.
We will randomly assign 110 patients to one of three conditions: 1) Standard treatment; 2) Traditional prize reinforcement; or 3) Early-treatment enhanced prize reinforcement.
Patients in each condition will receive counseling for their smoking based on current standard of care guidelines.
All patients will participate in a one-week baseline period, followed by a four-week intervention.
Throughout both phases, each patient will meet with a research assistant twice daily to provide carbon monoxide (CO) samples.
Patients in the prize reinforcement conditions will earn the chance to win prizes when they provide negative CO samples (i.e., < 6ppm).
They will also earn bonus draws if they provide negative cotinine samples (i.e., <100ng/ml) after weekends.
Patients in the Traditional CM condition will have at least a 50% chance of winning a prize for each negative sample with escalating chances for successive negative samples.
Patients in the Enhanced condition will have the opportunity to earn the same overall number of draws and magnitude of reinforcement, but the schedule of reinforcement will differ.
For the first week of the CM phase, these patients will have a 100% chance of winning prizes, but in the latter 3 weeks, overall probability of reinforcement will be decreased to 34%.
Patients will also undergo 2- and 6-month follow-up assessments.
Primary outcome measures will be longest duration of continuous abstinence and mean number of days of abstinence.
We predict that the prize reinforcement will reduce cigarette smoking to a greater extent than standard treatment.
We also predict that the Enhanced CM condition will lead to greater reductions in cigarette smoking relative to the Traditional CM condition, and that these changes may result in longer sustained abstinence from smoking throughout the study period.
Studietyp
Interventionell
Inskrivning (Faktisk)
84
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48207
- Wayne State University, Jefferson Avenue Research Clinic
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
13 år och äldre (Barn, Vuxen, Äldre vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- A current Fagerstrom scale score of 6 or greater;
- Age 13 years old or older (Under age 18, parental consent is required);
- Able to read and understand English.
Exclusion Criteria:
- Have current severe, uncontrolled psychiatric disorders (i.e., acute suicidality or psychosis);
- Have current substance dependence, other than nicotine or caffeine dependence;
- Are in recovery for pathological gambling; or
- Are already participating in other behavioral or medication smoking cessation programs.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Traditional Contingency Management
Standard treatment plus prize based contingency management.
|
Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Prize draws result in incentives on an intermittent schedule (50% of draws are prizes).
Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
|
|
Experimentell: Early Enhanced Contingency Management
Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
|
Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4).
Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
|
|
Aktiv komparator: Standard Treatment
Counseling and monitoring of smoking cessation.
|
Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Expired Carbon Monoxide
Tidsram: Baseline and treatment phases, 2-mont and 6-month follow up.
|
Baseline and treatment phases, 2-mont and 6-month follow up.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Self-reported smoking.
Tidsram: Baseline, throughout treatment, 2-month and 6-month follow up.
|
Baseline, throughout treatment, 2-month and 6-month follow up.
|
|
Cotinine levels.
Tidsram: Baseline, throughout treatment, 2-month and 6-month follow up.
|
Baseline, throughout treatment, 2-month and 6-month follow up.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: David M Ledgerwood, Ph.D., Wayne State University
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 augusti 2007
Primärt slutförande (Faktisk)
1 juli 2011
Avslutad studie (Faktisk)
1 juli 2011
Studieregistreringsdatum
Först inskickad
17 mars 2009
Först inskickad som uppfyllde QC-kriterierna
17 mars 2009
Första postat (Uppskatta)
19 mars 2009
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
28 juni 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
27 juni 2013
Senast verifierad
1 juni 2013
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RDA021839A
- R21DA021839 (U.S.S. NIH-anslag/kontrakt)
- 1R21DA021839-01 (U.S.S. NIH-anslag/kontrakt)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .